Table 2 Contraceptives reported to be associated with tumor growth
From: Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients
Contraceptive (Commercial name) | Type | Composition | Number of patients who experienced tumor growth | Number of patients who did not experience tumor growth |
|---|---|---|---|---|
Non-Ovlon | combined oral | 0.05 mg estrogen 1.0 mg noreethisteron acetate | 1 slight | 7 |
Marvelon | combined oral | 0.03 mg estrogen 0.15 mg desogestrel | 1 slight | 6 |
Femranette | combined oral | 0.03 mg estrogen 0.15 mg levonorgestrel | 1 slight | 1 |
Trisiston | combined oral | 0.03 mg estrogen 0.125 mg levonorgestrel | 1 slight | 1 |
Ovanon | combined oral | 0.05 mg estrogen 2.5 mg lynestrenol | 1 slight | 1 |
Depot-Clinovir | parenteral progestogen | 150 mg medroxyprogesterone acetat 200 mg norethisteron enanthat | 2 significant | 0 |